Bio-IT World January 23, 2026
The mood at this year’s J.P. Morgan Healthcare Conference signals a dramatic shift for biopharma dealmaking, with industry leaders projecting 2026 could eclipse last year’s surging merger and acquisition activity.
Speaking at an Endpoints News panel discussion moderated by John Carroll, founder and editor of Endpoints News, senior executives from AbbVie, Amgen, and Merck expressed confidence that favorable market conditions and breakthrough science are converging to create what one panelist called “a renaissance moment” for the sector.
“The momentum is there,” said Roel van der Akker, a partner at PwC who sponsored the discussion. He noted that 2025 proved to be “a tale of two halves,” with policy uncertainty weighing on deals early...
Today's Sponsors
Today's Sponsor